Latest in ovarian cancer treatment
Latest in ovarian cancer treatment
Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia
Master pathways and targets in T cell acute lymphoblastic leukaemia
Second-line and beyond in mCRC: Optimising the benefit and reducing the risk
Beyond second-line therapy: New hope for mCRC patients in Egypt
Multi-target kinase inhibitors: From data to practice
First- and second-line treatments for locally advanced renal cell carcinoma
Advanced HCC: New systemic treatment options
Highlights from IGILUC 2019
Pharmacology update from ONS 2019
Anti-cancer compound for brain cancer found in daffodils
ALK-positive NSCLC: Treatments and latest developments